500 patients67,039 observations150 daysLIVE

Patient P-03357

Synthetic patientONX-7 · Day 148 · 55–64 · M · baseline S02Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Unstable
Nutritional resilience
Improving
Discontinuation risk
49%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S02
  2. Day 101 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 102 CR-01 recommendedClinician Review CR-01
  4. Day 103 Patient acceptedStarted CR-01 in the companion
  5. Day 108 Deterioration detected before clinical escalationClinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 101.

Primary contributors, last 14 days
  • Nutritional resilience+8
  • Toxicity+6
  • GI instability-5
  • Inflammatory activity+5
  • Treatment adherence-4

What helped?

  • Clinician Review CR-01Day 102
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
52%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 81% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
2.2/10
worsening · -0.2 vs previous 14 d
Stress level
Daily log
5.4/10
improving · -0.3 vs previous 14 d
Pessimism score
Daily log
5.5/10
stable · +0.1 vs previous 14 d
Sleep quality
Wearable
32.1/100
improving · +1.1 vs previous 14 d
Libido
Daily log
2.5/10
stable · -0.1 vs previous 14 d
HRV
Wearable
58.6 ms
stable · +1.3 vs previous 14 d
Toxicity
Blood
47.2/100
improving · -1.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 31 from the failing basin, 58 from restoration.

Would help
  • GI-04 GI Support Protocol
    72% improved among 36 similar · onset 8 d · confidence 50%
  • ME-01 Monitoring Escalation
    100% improved among 11 similar · onset 3 d · confidence 53%
  • DT-01 Dosing / Timing Recommendation
    82% improved among 11 similar · onset 5 d · confidence 53%
  • More protein
    GI -4.2 next day on high-intake days · n 15
Would not help
  • AD-05 Adherence Support
    only 20% improved among 10 similar
  • Keep histamine low
    GI +3.7 next day on high-intake days · n 23
  • Keep fat low
    GI +3.5 next day on high-intake days · n 26
  • Keep lactose low
    GI +2.8 next day on high-intake days · n 19
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -4.2supporter · 95%
  • Histamine load
    +3.7detractor · 95%
  • Dietary fat load
    +3.5detractor · 95%
  • Lactose
    +2.8detractor · 91%
  • Caffeine
    +0.3no signal · 15%
  • Alcohol
    -0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 26/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 60
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • Daily logGI symptom score 52 and rising
    • WearableSleep 5.4 h, below personal baseline
  • Inflammatory signalling 50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 59
  • Drug metabolism and exposure 20
    • BloodToxicity index 47
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 26/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
55 ms
Sleep
5.4 h
Steps
5,379
Resting HR
67 bpm
Daily log: GI score 52, nutritional resilience 44, adherence 70.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0304648%S20GI-04no change53
P-0326048%S1954
P-0327143%S1966
P-0335243%S1959
P-0346542%S17CR-01improved65
P-0316441%S1158
P-0326741%S0562
P-0300438%S0356
P-0319138%S19GI-04improved51
P-0344438%S1762
P-0308037%S0962
P-0312337%S14GI-04improved50